SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
DUBLIN, Ireland, Aug. 24, 2017 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the Company will present at the Morgan Stanley 15th Annual Global Healthcare Conference at 10:30 a.m. ET on September 13, 2017 in New York City, NY.
The conference presentation will be webcast live and may be accessed by visiting Horizon's investor relations section of the website at http://ir.horizon-pharma.com. A replay of the webcast will be available for the event.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] Ruth Venning Executive Director, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Affairs & Chief Communications Officer [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
